CA2622975A1 - Agonistes du recepteur a3 de l'adenosine pour le traitement du syndrome de l'oeil sec - Google Patents
Agonistes du recepteur a3 de l'adenosine pour le traitement du syndrome de l'oeil sec Download PDFInfo
- Publication number
- CA2622975A1 CA2622975A1 CA002622975A CA2622975A CA2622975A1 CA 2622975 A1 CA2622975 A1 CA 2622975A1 CA 002622975 A CA002622975 A CA 002622975A CA 2622975 A CA2622975 A CA 2622975A CA 2622975 A1 CA2622975 A1 CA 2622975A1
- Authority
- CA
- Canada
- Prior art keywords
- dry eye
- agonist
- adenosine
- eye
- a3ar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000003556 Dry Eye Syndromes Diseases 0.000 title claims abstract 10
- 206010013774 Dry eye Diseases 0.000 title claims abstract 10
- 239000002593 adenosine A3 receptor agonist Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 101150046889 ADORA3 gene Proteins 0.000 claims abstract 10
- 238000000034 method Methods 0.000 claims abstract 10
- 239000000556 agonist Substances 0.000 claims abstract 9
- 239000000203 mixture Substances 0.000 claims abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 238000011200 topical administration Methods 0.000 claims 4
- HUJXGQILHAUCCV-MOROJQBDSA-N 3-iodobenzyl-5'-N-methylcarboxamidoadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 HUJXGQILHAUCCV-MOROJQBDSA-N 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- IPSYPUKKXMNCNQ-PFHKOEEOSA-N (2s,3s,4r,5r)-5-[2-chloro-6-[(3-iodophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC(Cl)=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 IPSYPUKKXMNCNQ-PFHKOEEOSA-N 0.000 claims 2
- XTPOZVLRZZIEBW-SCFUHWHPSA-N (2r,3r,4s,5r)-2-[6-[2-(4-aminophenyl)ethylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=CC(N)=CC=C1CCNC1=NC=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XTPOZVLRZZIEBW-SCFUHWHPSA-N 0.000 claims 1
- LDYMCRRFCMRFKB-MOROJQBDSA-N (2s,3s,4r,5r)-5-[6-[(4-aminophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C=CC(N)=CC=3)=C2N=C1 LDYMCRRFCMRFKB-MOROJQBDSA-N 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 206010015958 Eye pain Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 206010047513 Vision blurred Diseases 0.000 claims 1
- 208000008784 apnea Diseases 0.000 claims 1
- MWEQTWJABOLLOS-UHFFFAOYSA-L disodium;[[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;trihydrate Chemical compound O.O.O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP([O-])(=O)OP(O)([O-])=O)C(O)C1O MWEQTWJABOLLOS-UHFFFAOYSA-L 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004356 excessive tearing Diseases 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- 230000007803 itching Effects 0.000 claims 1
- 230000035807 sensation Effects 0.000 claims 1
- 208000032023 Signs and Symptoms Diseases 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76250606P | 2006-01-27 | 2006-01-27 | |
| US60/762,506 | 2006-01-27 | ||
| PCT/IL2006/000130 WO2007086044A1 (fr) | 2006-01-27 | 2006-02-01 | Agonistes du récepteur a3 de l'adénosine pour le traitement du syndrome de l'œil sec |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2622975A1 true CA2622975A1 (fr) | 2007-08-02 |
| CA2622975C CA2622975C (fr) | 2011-05-03 |
Family
ID=36794417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2622975A Expired - Fee Related CA2622975C (fr) | 2006-01-27 | 2006-02-01 | Agonistes du recepteur a3 de l'adenosine pour le traitement du syndrome de l'oeil sec |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1976494A1 (fr) |
| JP (2) | JP5185139B2 (fr) |
| KR (1) | KR101037095B1 (fr) |
| CN (1) | CN101365430B (fr) |
| AU (1) | AU2006336834B2 (fr) |
| BR (1) | BRPI0621052A2 (fr) |
| CA (1) | CA2622975C (fr) |
| IL (1) | IL191271A (fr) |
| WO (1) | WO2007086044A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE034474T2 (en) | 2007-03-14 | 2018-02-28 | Can Fite Biopharma Ltd | Method for the synthesis of IB-meca |
| IL184620A0 (en) * | 2007-07-15 | 2008-01-20 | Can Fite Biopharma Ltd | Composition for the treatment of inflammation |
| ES2531828T3 (es) | 2008-03-31 | 2015-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Derivados de purina como agonistas selectivos de los receptores A3 de adenosina |
| US8916570B2 (en) | 2008-03-31 | 2014-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor agonists and antagonists |
| US9181253B2 (en) | 2008-08-01 | 2015-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adenosine receptor agonists, partial agonists, and antagonists |
| AU2009276411B2 (en) | 2008-08-01 | 2014-08-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor antagonists and partial agonists |
| JP5849044B2 (ja) * | 2009-05-17 | 2016-01-27 | キャン−ファイト バイオファーマ リミテッド | 眼圧低下のためのａ３アデノシン受容体作動薬 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5900407A (en) * | 1997-02-06 | 1999-05-04 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with uridine triphosphates and related compounds |
| JPH10158188A (ja) * | 1996-11-29 | 1998-06-16 | Senju Pharmaceut Co Ltd | 角膜治療用組成物 |
| IL133680A0 (en) * | 1999-09-10 | 2001-04-30 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
| CA2500360A1 (fr) * | 2002-09-27 | 2004-04-08 | Bioenvision, Inc. | Methodes et compositions pour traiter des troubles auto-immunes a l'aide de clofarabine |
| JPWO2005121320A1 (ja) * | 2004-06-10 | 2008-04-10 | 協和醗酵工業株式会社 | 幹細胞自己複製促進剤 |
| WO2006011130A1 (fr) * | 2004-07-28 | 2006-02-02 | Can-Fite Biopharma Ltd. | Agonistes de recepteur de l'adenosine a3 pour le traitement de troubles de l'oeil sec comprenant le syndrome de sjogren |
-
2006
- 2006-02-01 BR BRPI0621052-0A patent/BRPI0621052A2/pt not_active IP Right Cessation
- 2006-02-01 JP JP2008551950A patent/JP5185139B2/ja not_active Expired - Fee Related
- 2006-02-01 AU AU2006336834A patent/AU2006336834B2/en not_active Ceased
- 2006-02-01 CN CN2006800475697A patent/CN101365430B/zh not_active Expired - Fee Related
- 2006-02-01 EP EP06701840A patent/EP1976494A1/fr not_active Withdrawn
- 2006-02-01 CA CA2622975A patent/CA2622975C/fr not_active Expired - Fee Related
- 2006-02-01 WO PCT/IL2006/000130 patent/WO2007086044A1/fr active Application Filing
- 2006-02-01 KR KR1020087020322A patent/KR101037095B1/ko not_active IP Right Cessation
-
2008
- 2008-05-06 IL IL191271A patent/IL191271A/en not_active IP Right Cessation
-
2012
- 2012-11-12 JP JP2012248668A patent/JP2013032396A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN101365430A (zh) | 2009-02-11 |
| WO2007086044A1 (fr) | 2007-08-02 |
| AU2006336834A1 (en) | 2007-08-02 |
| IL191271A (en) | 2014-03-31 |
| KR101037095B1 (ko) | 2011-05-26 |
| AU2006336834B2 (en) | 2009-12-10 |
| JP2013032396A (ja) | 2013-02-14 |
| IL191271A0 (en) | 2009-08-03 |
| CN101365430B (zh) | 2011-09-21 |
| BRPI0621052A2 (pt) | 2012-07-17 |
| JP5185139B2 (ja) | 2013-04-17 |
| JP2009524647A (ja) | 2009-07-02 |
| KR20080090517A (ko) | 2008-10-08 |
| CA2622975C (fr) | 2011-05-03 |
| EP1976494A1 (fr) | 2008-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2622975A1 (fr) | Agonistes du recepteur a3 de l'adenosine pour le traitement du syndrome de l'oeil sec | |
| Rennard et al. | Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4 | |
| Partinen et al. | Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study—the PRELUDE study | |
| JP5339916B2 (ja) | 骨関節炎の治療におけるａ３アデノシン受容体アゴニストの使用 | |
| Hansen et al. | Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis | |
| US7825102B2 (en) | Treatment of dry eye conditions | |
| MX2010006326A (es) | Comprimidos de desintegracion oral que comprenden difenhidramina. | |
| WO2006011130A1 (fr) | Agonistes de recepteur de l'adenosine a3 pour le traitement de troubles de l'oeil sec comprenant le syndrome de sjogren | |
| NO343597B1 (no) | Anvendelse av testosteron og en 5-HT1A-agonist ved behandling av seksuell dysfunksjon | |
| Wilson et al. | Effects of 5 weeks of administration of fluoxetine and dothiepin in normal volunteers on sleep, daytime sedation, psychomotor performance and mood | |
| Sabbah et al. | Azelastine eye drops in the treatment of seasonal allergic conjunctivitis or rhinoconjunctivitis in young children | |
| Shinotoh et al. | Lamotrigine trial in idiopathic parkinsonism: a double‐blind, placebo‐controlled, crossover study | |
| Huang et al. | A double-blind, randomized, comparative study to evaluate the efficacy and safety of zaleplon versus zolpidem in shortening sleep latency in primary insomnia | |
| JP2008520672A (ja) | チプラナビルとダルナビルの共投与によるｈｉｖ感染症の治療方法 | |
| ES2678122T3 (es) | Comprimidos bucales mucoadherentes para el tratamiento del herpes orofacial | |
| RU2012138043A (ru) | Агонисты а3аr для лечения увеита | |
| KR101971762B1 (ko) | 성기능장애의 치료에 사용하기 위한 a3 아데노신 수용체 리간드 | |
| JP2015524465A5 (fr) | ||
| Tamgadge et al. | Meth Mouth: A review on methamphetamine abuse, its oral manifestations and the role of a dentist. | |
| WO2024074850A1 (fr) | Traitement de troubles mentaux | |
| WO2005027968A1 (fr) | Medicament contre le syndrome de down | |
| JP2012526798A5 (fr) | ||
| AU2010250759B2 (en) | A3 adenosine receptor agonists for the reduction of intraocular pressure | |
| Sharara | Airway and Cardio Vascular Responses to Nebulized Glyceryl Trinitrate in Normal Subjects | |
| Bone | Ginkgo and Ear Disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20160201 |
|
| MKLA | Lapsed |
Effective date: 20160201 |